Irma Bagdoniene: Lowering LDL May Alter Inflammatory and Oxidative Pathways
Irma Bagdoniene, Cardiologist and Lipidologist at Klinikum Lippe – University Hospital for Cardiology, Angiology, and Internal Intensive Care Medicine, posted on LinkedIn:
“Lowering lipids — but increasing oxidation?
A new study by Koutsogianni et al. (2025) looked at people with high Lp(a) and found something unexpected:
– Statins and ezetimibe raised oxidized phospholipids on apoB and apo(a), reduced those on plasminogen,
– while PCSK9 inhibitors had no clear effect.
So even when we lower LDL cholesterol, other inflammatory and oxidative processes may change in ways we don’t yet understand.
The message is clear: we need more studies to understand how lipid-lowering therapies truly affect the biology of Lp(a).”
Title: Effect of lipid-lowering medications on oxidized phospholipids in individuals with elevated LIPOPROTEIN(a)
Authors: Amalia Despoina Koutsogianni, Fotios Barkas, Constantinos Tellis, Alexandros Tselepis, George Liamis, Sotirios Tsimikas, Evangelos Liberopoulos

Read full article here.
Stay updated with Hemostasis Today.
-
Aug 12, 2026, 08:33Craig Clapper: What the Andrea Doria Collision Teaches Us About Safety
-
Aug 12, 2026, 08:16Chengyong Yang: Can Plasma Reveal Cell Specific Signals
-
Aug 12, 2026, 07:49Alan Dursun: Phnom Penh, Cambodia – Part 3 – Turning Partnership into Action
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?
-
Aug 12, 2026, 06:24Lucas Jae: How Mitochondria Sense Heme Scarcity to Regulate Heme and Globin Production
-
Aug 12, 2026, 06:09Luis Tam։ New CDC Global Health Security Funding Opportunities
-
Aug 12, 2026, 06:09Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
-
Aug 12, 2026, 06:01Sophie He: Exploring Manufacturing Scalability and Cell Separation